ReviewJournal of clinical medicine2025
Advances in Understanding Inflammation and Tissue Damage: Markers of Persistent Sequelae in COVID-19 Patients.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cardiopulmonary crosstalk in Long COVID: a systematic review of emerging evidence.BMC cardiovascular disorders · 2025Pooled it
- Subclinical neurovascular and immune correlates of post-COVID-19 syndrome detected by retinal imaging.Brain, behavior, & immunity - health · 2026Article
- Cytokine-Driven Hyperinflammation in Long COVID: Mechanisms, Biomarkers, Complement Dysregulation, and Emerging Immunotherapies-A Narrative Review.Health science reports · 2026Article
- Neurodegenerative and Cognitive Consequences of Long COVID.International journal of molecular sciences · 2026Review
- Impact of COVID-19 on inflammatory disease research: a literature analysis of 77,575 PubMed articles.Reumatologia · 2026Article
- Persistent mitochondrial and endothelial dysfunction in non-hospitalized patients with Long COVID.Frontiers in medicine · 2026Article
- Quorum sensing geneFrontiers in microbiology · 2026Article
- Lingering echoes of SARS-CoV-2: mechanistic insights and management of long COVID syndrome.Inflammopharmacology · 2026Review
- Glial activation and increase in cerebral pro-inflammatory cytokine expression in a female animal post-COVID model.Brain, behavior, & immunity - health · 2025Article
- Targeting the NLRP3 inflammasome with natural products for ischemia-reperfusion injury across organs: mechanisms, structure-activity relationships, and delivery innovations.Inflammopharmacology · 2025Review
- High Free IgE and Mast Cell Activation in Long COVID: Mechanisms of Persistent Immune Dysregulation.Life (Basel, Switzerland) · 2025Article
- Impact of inflammation levels on the liver during the COVID-19 pandemic: a mediation analysis.BMC public health · 2025Article
- Article
- Review
- Immunomodulatory Mechanisms Underlying Neurological Manifestations in Long COVID: Implications for Immune-Mediated Neurodegeneration.International journal of molecular sciences · 2025Review
- Article
- Long-Term Effects of COVID-19 on Women's Reproductive Health and Its Association with Autoimmune Diseases, Including Multiple Sclerosis.Journal of clinical medicine · 2025Review
- Acute pulmonary inflammatory reaction in COVID-19 - histological and immunohistochemical study.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review explores the crucial role of established and emerging biomarkers in the diagnosis, management, and understanding of post-COVID-19 conditions. With COVID-19 affecting multiple organ systems, biomarkers have been instrumental in identifying ongoing inflammation and tissue damage, facilitating early diagnosis and prognostication. Specifically, markers like C-reactive protein (CRP), interleukin-6 (IL-6), and novel entities such as soluble urokinase plasminogen activator receptor (suPAR) and neutrophil extracellular traps (NETs) provide insights into the pathophysiological mechanisms and predict long-term outcomes. This review highlights the integration of these biomarkers into clinical workflows and their implications for personalized medicine, emphasizing their potential in guiding therapeutic interventions and monitoring recovery. Future directions suggest a focus on longitudinal studies to explore biomarker trajectories and their interaction with therapeutic outcomes, aiming to enhance the management of post-COVID-19 conditions and refine public health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.